CD10 expression by melanoma cells is associated with aggressive behavior in vitro and predicts rapid metastatic progression in humans.
J Dermatol Sci
; 69(2): 105-13, 2013 Feb.
Article
en En
| MEDLINE
| ID: mdl-23219141
ABSTRACT
BACKGROUND:
No biological or molecular marker of primary melanoma tumor cells has been shown to predict clinical outcome in melanoma.OBJECTIVE:
To determine whether CD10, CD133, nestin and CD20 may evaluate the prognosis of melanoma.METHODS:
The differential expression of these molecules was assessed in pairs of cell lines. We evaluated, by both immunohistochemical staining and RT-qPCR, their expression in a cohort of 32 patients (68 samples) with a history of metastatic melanoma, divided into two groups according to their clinical outcome profile.RESULTS:
CD10 over expression in cancer cell lines was associated with more aggressive behavior in vitro. A CD10-positive staining was more frequent in patients in the "rapidly progressive" group than those in the "long survivor" group (23/35 versus 2/18, p<10(-4)). CD10 expression was associated with a lower median overall survival (1.15 year - IQR [0.50-2.58] versus 4.27 - IQR [1.66-6.33]; p=10(-4)). The Odds Ratio of displaying a "rapidly progressive" melanoma when tumor cells expressed CD10 was 15 (95% confidence interval [3-78]). After adjusting for confounding factors, CD10 expression in melanoma tumor cells remained associated with an increased risk of death and more rapid disease progression (p=6×10(-4); HR=3.71).CONCLUSION:
CD10 may predict clinical outcome in melanoma patients.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Cutáneas
/
Neprilisina
/
Melanoma
Tipo de estudio:
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Revista:
J Dermatol Sci
Asunto de la revista:
DERMATOLOGIA
Año:
2013
Tipo del documento:
Article